1. Home
  2. ROIV vs BFAM Comparison

ROIV vs BFAM Comparison

Compare ROIV & BFAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ROIV
  • BFAM
  • Stock Information
  • Founded
  • ROIV 2014
  • BFAM 1986
  • Country
  • ROIV United Kingdom
  • BFAM United States
  • Employees
  • ROIV N/A
  • BFAM N/A
  • Industry
  • ROIV Biotechnology: Pharmaceutical Preparations
  • BFAM Other Consumer Services
  • Sector
  • ROIV Health Care
  • BFAM Consumer Discretionary
  • Exchange
  • ROIV Nasdaq
  • BFAM Nasdaq
  • Market Cap
  • ROIV 7.8B
  • BFAM 7.1B
  • IPO Year
  • ROIV N/A
  • BFAM 1997
  • Fundamental
  • Price
  • ROIV $10.99
  • BFAM $129.36
  • Analyst Decision
  • ROIV Buy
  • BFAM Buy
  • Analyst Count
  • ROIV 4
  • BFAM 8
  • Target Price
  • ROIV $17.50
  • BFAM $139.13
  • AVG Volume (30 Days)
  • ROIV 5.1M
  • BFAM 560.0K
  • Earning Date
  • ROIV 05-29-2025
  • BFAM 05-05-2025
  • Dividend Yield
  • ROIV N/A
  • BFAM N/A
  • EPS Growth
  • ROIV N/A
  • BFAM 93.82
  • EPS
  • ROIV N/A
  • BFAM 2.77
  • Revenue
  • ROIV $29,053,000.00
  • BFAM $2,728,831,000.00
  • Revenue This Year
  • ROIV N/A
  • BFAM $9.64
  • Revenue Next Year
  • ROIV N/A
  • BFAM $7.16
  • P/E Ratio
  • ROIV N/A
  • BFAM $46.66
  • Revenue Growth
  • ROIV N/A
  • BFAM 9.71
  • 52 Week Low
  • ROIV $8.73
  • BFAM $100.59
  • 52 Week High
  • ROIV $13.06
  • BFAM $141.90
  • Technical
  • Relative Strength Index (RSI)
  • ROIV 52.59
  • BFAM 57.47
  • Support Level
  • ROIV $10.59
  • BFAM $127.28
  • Resistance Level
  • ROIV $11.37
  • BFAM $132.99
  • Average True Range (ATR)
  • ROIV 0.32
  • BFAM 3.30
  • MACD
  • ROIV -0.01
  • BFAM 0.52
  • Stochastic Oscillator
  • ROIV 52.23
  • BFAM 64.47

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About BFAM Bright Horizons Family Solutions Inc.

Bright Horizons Family Solutions Inc provider of early education and child care, family care solutions, and workforce education services that help working families and client employees personally and professionally. It provides services under multi-year contracts with employers that offer early education and child care, back-up care, and educational advisory services as part of their employee benefits package. The company has three business segments; full-service center-based child care, backup care, and educational advisory services. The majority of the revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, and Others.

Share on Social Networks: